Budget Amount *help |
¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
Outline of Final Research Achievements |
Myelodysplastic syndrome (MDS) has a varied clinical course, with some patients remaining asymptomatic with mild cytopenia for a long time, while others show progressive leukemia a short time after the diagnosis. In the present study, we analyzed whether epigenetic alternation could contribute to the disease progression of MDS. It is suggested that alteration of oncogene expression is regulated by histone modification. This study suggested a new role of epigenetic alternation in the disease progression of MDS and possibilities of these processes as new targets of novel molecular therapy.
|